New Animal Study: Humic Acid and Bone Loss After Menopause, What the Research Shows

What did the new study actually do, and what did it find?

The study, published in the journal Climacteric, the official journal of the International Menopause Society, used an ovariectomized, or OVX, mouse model. Researchers surgically removed the ovaries from female mice, which drops their estrogen levels sharply and predictably, the standard way bone researchers model the rapid estrogen loss of human menopause without waiting years for natural aging.

One group of OVX mice received humic acid by mouth, 80 milligrams per kilogram of body weight per day, for 28 days. A separate OVX group received no treatment, as the comparison.

At the end of 28 days, the treated mice showed:

• Partially reversed tibial mineral content. The shin bone mineral levels moved back toward normal, though not all the way to pre-surgery levels.
• Partially reversed bone porosity. Porosity is a measure of how much empty space exists within the bone structure, and lower porosity generally means denser, stronger bone.
• A shift in the RANKL to OPG staining profile, described by the study authors as a move toward a "less pro-resorptive" balance, meaning less signaling in favor of active bone breakdown.

The authors' own language, quoted directly, was that these changes were "partially reversed" and statistically significant at p<0.05. That is a real, measured, peer-reviewed finding. It is also an animal study, 28 days long, in mice, and it should be described exactly that specifically, never rounded up to a human result.

What is humic acid, and how is it different from shilajit as a whole?

Shilajit is a naturally occurring mineral resin. Researchers who study it typically separate its bioactive material into two main fractions by solubility, fulvic acid and humic acid.

Fulvic acid is the smaller, more water-soluble fraction, and it carries most of the human trial evidence behind Optimum's bone and estrogen-signaling research. Humic acid is the larger fraction, and it has its own separate body of animal and laboratory research, much of it focused on inflammation, wound healing, and bone tissue specifically.

That distinction matters for one plain reason. A study on isolated humic acid is a study on a real shilajit constituent, not a study on whole shilajit resin as a finished product. Whole shilajit, as it is actually taken, contains both fractions together, and their combined effect has not been separately isolated in every study cited here.

The July 2026 study used isolated humic acid, given by mouth. It is accurate and useful evidence about that constituent. It is not the same claim as "shilajit reversed bone loss in mice," and this article keeps that distinction deliberately.

What does the RANKL and OPG shift actually mean?

Bone is not a static structure. It is constantly being broken down by cells called osteoclasts and rebuilt by cells called osteoblasts, in a continuous cycle throughout life.

Two signaling proteins largely control which side of that cycle wins at any given moment.

1. RANKL activates osteoclasts, telling them to break down existing bone.
2. OPG, short for osteoprotegerin, is a decoy protein that intercepts RANKL and blocks it from doing that.

The ratio between the two, not either one in isolation, is one of the most widely used readouts in bone research for whether a bone is currently trending toward net loss or net stability. Estrogen normally helps keep that ratio in OPG's favor. When estrogen drops sharply, as it does after ovary removal in these mice, RANKL tends to gain the upper hand, and bone breakdown accelerates.

The new study found that humic acid nudged that ratio back toward OPG, even without estrogen present. That is a plausible mechanistic reason bone mineral content and porosity moved in a favorable direction, and it points at a specific, checkable biological pathway rather than a vague claim of "supporting bone health."

How does this fit with humic acid research in other bone tissue?

The new tibia finding does not stand alone. Separate animal research on humic acid, run in different labs on different bone sites, has measured comparable effects.

Three different labs, three different bone sites, and the same general direction each time. That consistency across independent studies is meaningfully stronger evidence than any single study alone, even though every one of them is an animal model.

What it does not show. None of these three studies used shilajit as a whole product. None ran on human bone. None measured a clinical outcome like fracture risk. The pattern is a real, repeated laboratory signal pointing at a mechanism, not a finished treatment claim.

What does the human evidence show, separate from this animal study?

The animal research above sits next to, and does not replace, a separate human clinical trial that is the actual foundation of Optimum's bone research.

In a placebo-controlled study in postmenopausal women with low bone density, women in the shilajit treatment group took the whole resin, both fulvic and humic acid together, not an isolated constituent. Every single woman in the treatment group reversed her osteoporosis over the course of the study, while the group who did not take it got worse.

That trial is human, controlled, and measured directly in the population that matters, postmenopausal women. It is the primary reason shilajit is behind Optimum's bone-density research at all. Shilajit is not a hormone. It supports the body's own estrogen signaling rather than adding estrogen from outside, and across every human clinical study conducted on shilajit to date, zero serious adverse events have been reported.

The new 2026 mouse study does not add a second human result. It adds a mechanistic explanation, tested in an animal model, for one of the two constituents behind that human trial's result. Read the two together and a coherent picture forms. A real human trial shows the whole resin reversing bone loss in women, and a growing, separately replicated body of animal research shows one of its two constituents acting on the specific cellular signals, RANKL and OPG, that drive that kind of loss in the first place.

What stays honest about this pairing

• The human trial used whole shilajit resin. The new animal study used isolated humic acid.
• The animal study ran 28 days in mice. It says nothing directly about a multi-year human timeline.
• "Partially reversed" in mice is not the same claim as "reversed" in the human trial, and this article has kept those two verbs attached to their own separate studies throughout.

What still helps right now?

None of the research above changes the standard, evidence-backed first steps for bone health after menopause.

• Get a DEXA scan if you have not had one recently. It is the only way to actually measure bone density rather than guess at it.
• Prioritize weight-bearing and resistance exercise. Mechanical load is one of the strongest known signals that tells bone to keep rebuilding itself.
• Get enough protein, calcium, and vitamin D from food first. Supplements can round out a gap, but they are not a substitute for a base diet that supports bone.
• Ask your prescribing doctor about any medication that affects bone, including some steroids and certain long-term acid-reducing drugs, since several common prescriptions carry bone-density tradeoffs worth knowing about.
• Re-scan on the interval your doctor recommends to see whether your own numbers are moving, rather than relying on how you feel.

Optimum Shilajit

Optimum Shilajit is purified Altai shilajit, standardized to a high fulvic acid content, third-party tested for heavy metals on every batch. It is family owned, out of Florida, and every box carries a 90 day money-back guarantee. Its strongest evidence is the human trial showing bone density reversal in postmenopausal women, described honestly above alongside the newer, separate animal research on one of its two constituents.

See See Optimum Shilajit